Tocilizumab (Tyenne)

Tyenne (Tocilizumab) is a biologic medicine that suppresses an overactive immune system in order to treat rheumatoid arthritis, giant-cell arteritis and some types of juvenile arthritis.

Tyenne works by blocking a receptor on the surface of cells that’s related to the body’s immune response: the interleukin-6 receptor (IL-6R).

This medication is often given in combination with methotrexate.

It can take 6-12 weeks to feel the effects of Tyenne.

Biosimilar

Tyenne is a type of medicine that is called a biosimilar. A biosimilar is a type of biologic medication that is designed to be identical to an existing biologic medication, but is created using a different process.

Tyenne is a biosimilar of Actemra. Both medications are known by the same generic name: tocilizumab. Biosimilars are often cheaper than the original medication.

Taking Tyenne

Tyenne is available as an injection (Tyenne SC) and as an intravenous infusion (Tyenne IV). The injection can be done quickly at home. The infusion is done every 4 weeks at a specialized infusion clinic.

Important Tests and Risks

Science

Safety

Tyenne Video

Watch rheumatologist Dr. Andy Thompson introduce Tyenne in a short 3-minute video:

Resources

Tyenne IV Quick Reference Guide
Tyenne SC Quick Reference Guide
Pregnancy & Medications Quick Reference Guide

DIN

  • 02552477 (IV)
  • 02552485 (IV)
  • 02552450 (IV)
  • 02552469 (IV)
  • 02552493 (SC)